A2 cont 20. (Amended) The method of claim [17] 1 wherein said [solid] resectable malignant tumor is an early-stage solid tumor.

Sub Y33 23. (Amended) A method for preventing post-operative infection comprising administering an immunostimulatory dosage of an α-interferon composition to a human before surgery, wherein said immunostimulatory dosage is about 4,000,000 U/m^2 per day or less.

24. (Amended) An article of manufacture comprising packaging material and an α-interferon composition contained within said packaging material, wherein said packaging material comprises a label or package insert indicating that administration of an immunostimulatory dosage of said α-interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having said malignant tumor, wherein said immunostimulatory dosage is about 4,000,000 U/m^2 per day or less.

A3 25. (Amended) An article of manufacture comprising packaging material and an α-interferon composition contained within said packaging material, wherein said packaging material comprises a label or package insert indicating that administration of an immunostimulatory dosage of said α-interferon composition in conjunction with treating said patient using effective non-surgical medical methodologies for diminishing said malignant tumor can be effective for treating a human patient having said malignant tumor, wherein said immunostimulatory dosage is about 1,000,000 U/m^2 per day or less.

26. (Amended) A method for treating a human patient having a non-resectable malignant tumor, comprising administering an immunostimulatory dosage of an α-interferon composition to said patient and treating said patient with effective non-surgical medical methodologies to diminish said tumor, wherein said immunostimulatory dosage is about 1,000,000 U/m^2 per day or less.